Cargando…

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

Background: Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for trial patients. New predictive and prognostic biomarkers validated in the general mCRC population are needed. Caudal-type homeobox 2 (CDX2) is an intestine-specific transcription factor with potential p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aasebø, Kristine, Dragomir, Anca, Sundström, Magnus, Mezheyeuski, Artur, Edqvist, Per-Henrik, Eide, Geir Egil, Ponten, Fredrik, Pfeiffer, Per, Glimelius, Bengt, Sorbye, Halfdan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026487/ https://www.ncbi.nlm.nih.gov/pubmed/32117703 http://dx.doi.org/10.3389/fonc.2020.00008

Ejemplares similares

Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients
por: Aasebø, Kristine Ø., et al.
Publicado: (2019)

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
por: Sorbye, Halfdan, et al.
Publicado: (2015)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
por: Siesing, Christina, et al.
Publicado: (2017)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer
por: Birgisson, Helgi, et al.
Publicado: (2015)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
por: Osterlund, Emerik, et al.
Publicado: (2022)

The Immune Landscape of Colorectal Cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2021)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2016)

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
por: Sclafani, Francesco, et al.
Publicado: (2018)

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer
por: Tarpgaard, Line S., et al.
Publicado: (2016)

Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis
por: Kundu, Snehangshu, et al.
Publicado: (2021)

Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
por: Thomsen, Maria, et al.
Publicado: (2018)

Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2017)

Let-7 miRNA-binding site polymorphism in the KRAS 3(′)UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2012)

Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
por: Angelsen, Jon-Helge, et al.
Publicado: (2015)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

Mitochondrial Respiration in KRAS and BRAF Mutated Colorectal Tumors and Polyps
por: Rebane-Klemm, Egle, et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer
por: Hu, Jing, et al.
Publicado: (2016)

Associations of Anthropometric Factors with KRAS and BRAF Mutation Status of Primary Colorectal Cancer in Men and Women: A Cohort Study
por: Brändstedt, Jenny, et al.
Publicado: (2014)

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
por: Yokota, Tomoya
Publicado: (2012)

KRAS and BRAF mutational status in colon cancer from Albanian patients
por: Martinetti, Daniela, et al.
Publicado: (2014)

KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia
por: Juárez, Miriam, et al.
Publicado: (2017)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates
por: Al-Salam, Suhail, et al.
Publicado: (2020)

Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study
por: Wangefjord, Sakarias, et al.
Publicado: (2013)

MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers
por: Choi, Yong Won, et al.
Publicado: (2016)

One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status
por: Myte, Robin, et al.
Publicado: (2018)

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
por: Popovici, Vlad, et al.
Publicado: (2013)

Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations
por: Li, Wenbin, et al.
Publicado: (2015)

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
por: Huang, Chi-Jung, et al.
Publicado: (2016)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
por: Won, Daeyoun David, et al.
Publicado: (2017)

Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation
por: Udo, Emiko, et al.
Publicado: (2017)

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
por: Li, Zi-Nan, et al.
Publicado: (2020)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_07itehtojtsnp5putfr9kn4vf6